Form 4: Travere Therapeutics Officer Sells Shares

Travere Therapeutics' Chief Legal Officer, Elizabeth E. Reed, exercised stock options and subsequently sold 10,000 shares under a pre-arranged 10b5-1 plan.

Summary

• Elizabeth E. Reed, Chief Legal Officer and General Counsel of Travere Therapeutics, Inc. (TVTX), reported transactions on September 22, 2025.
• Reed exercised 10,000 employee stock options at a price of $19.08 per share.
• Concurrently, Reed sold 10,000 shares of common stock at a price of $25.00 per share.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on June 16, 2025.
• Following these transactions, Reed beneficially owns 89,878 shares of Travere Therapeutics common stock.
• The reported beneficial ownership includes 396 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 31, 2025.
• The exercised stock option was fully vested and exercisable, originally granted on January 4, 2017, with an expiration date of January 4, 2027.

Sentiment

Score: 6

Explanation: The transaction reflects an insider monetizing vested options at a profit, which is a positive for the individual. The use of a 10b5-1 plan indicates adherence to compliance. While it's an insider sale, the pre-planned nature and relatively small volume suggest it's a routine financial event rather than a signal of negative sentiment towards the company's future.

Positives

• A company officer realized a profit by exercising stock options at $19.08 and selling the shares at $25.00, indicating personal financial benefit from company stock performance.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which demonstrates a commitment to transparent and compliant insider trading practices.

Negatives

• An insider selling shares, even under a 10b5-1 plan, could be perceived by some investors as a lack of conviction in the company's near-term stock price appreciation, although this is a routine event for option exercises.

Future Outlook

This Form 4 filing reports past insider transactions and does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing reports a routine insider transaction (exercise of options and sale of shares) by a company executive. Such transactions are common across all industries for executives with equity compensation and do not inherently reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The transaction is a routine insider sale under a pre-arranged plan and is unlikely to have a significant direct impact on the company's operational performance or strategic direction. It represents a small percentage of the company's outstanding shares.
• Employees: No direct impact on employees is indicated by this transaction.
• Management: The Chief Legal Officer executed a personal financial transaction in accordance with company policy and regulatory requirements.

Key Dates

Keywords

Travere Therapeutics, TVTX, insider trading, stock option, 10b5-1 plan, SEC Form 4, Elizabeth E. Reed, Chief Legal Officer